ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

TAK Takeda Pharmaceutical Company Ltd

13,10
0,02 (0,15%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Takeda Pharmaceutical Company Ltd TAK NYSE Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
0,02 0,15% 13,10 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
13,07 13,03 13,12 13,10 13,08
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202414:00BWTakeda Signs Option Agreement with Ascentage Pharma to Enter..
11/6/202414:00BWTakeda Announces Partnership Expansion with Partners In..
03/6/202412:45BWTakeda’s TAK-861 Phase 2b Late-Breaking Data Presentations..
01/6/202414:00BWTakeda and Pfizer Announce Four-Year Results from Positive..
31/5/202415:57BWTakeda Receives Positive CHMP Opinion for Recombinant..
21/5/202412:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/5/202414:02PRNCATakeda Canada Inc. conclut une lettre d'intention avec..
14/5/202414:00BWTakeda to Present Oncology Portfolio and Pipeline Data at..
10/5/202413:03BWTakeda annonce ses résultats pour l’exercice 2023 et ses..
09/5/202423:07BWTakeda veröffentlicht Ergebnisse für das Geschäftsjahr 2023,..
09/5/202408:07BWTakeda Announces FY2023 Full Year Results and FY2024..
26/4/202414:30BWTakeda Receives Positive CHMP Opinion for Fruquintinib in..
23/4/202413:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
22/4/202410:10PRNUSTakeda, Astellas and Sumitomo Mitsui Banking Announce Master..
19/4/202401:00BWU.S. FDA Approves Subcutaneous Administration of Takeda’s..
08/4/202414:00BWTakeda Announces New U.S. Corporate Social Responsibility..
27/3/202413:56PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/3/202413:53PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/3/202406:01BWTakeda gibt Kandidaten für den Vorstand bei der kommenden..
27/3/202400:07BWTakeda Announces Candidates for Board of Directors at..
26/3/202413:00BWTakeda Announces Approval of ADZYNMA® Intravenous Injection..
21/3/202414:39BW武田薬品、Ph+..
21/3/202408:33BWTakeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch..
20/3/202420:18BWTakeda annonce l'approbation par la FDA des États-Unis d'une..
19/3/202417:20BWTakeda Announces U.S. FDA Approval of Supplemental New Drug..
19/3/202411:30GLOBECENTOGENE Extends Strategic Partnership With Takeda to..
13/3/202413:00BWTakeda Announces Positive Topline Results from Phase 2 Study..
28/2/202413:03BW武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力
27/2/202423:26BWTakeda et Biological E. Limited s’associent pour accélérer..
27/2/202413:38BWTakeda und Biological E. Limited arbeiten zusammen, um den..
27/2/202405:30BWTakeda and Biological E. Limited Collaborate to Accelerate..
26/2/202413:00PRNCAFaire entendre sa voix à l'occasion de la Journée des..
12/2/202414:00BWFDA Approves Takeda’s EOHILIA (budesonide oral suspension),..
09/2/202400:00BWTakeda Intends to Rapidly Initiate the First Global Phase 3..
01/2/202422:23BWTakeda gibt Nachfolger für die Position des Chief Financial..
01/2/202422:18BWTakeda annonce la succession de son directeur financier
01/2/202415:59BWTakeda annonce ses résultats pour le troisième trimestre de..
01/2/202412:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202407:54BWTakeda Announces Chief Financial Officer Succession
01/2/202407:02BWTakeda Announces Third-Quarter FY2023 Results; On-Track..
30/1/202417:00BW武田薬品、慢性炎症性脱髄性多発根神経炎(CIDP)に対する維持療法としてのHYQVIA®について、欧州委員会から承認を獲得
30/1/202414:04BWTakeda-Arzneimittel HYQVIA ® von der Europäischen Kommission..
29/1/202419:55BWLe HYQVIA® de Takeda approuvé par la Commission européenne..
29/1/202417:10BWTakeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults..
29/1/202408:00BWTakeda’s HYQVIA® Approved by European Commission as..
25/1/202423:00PRNUSCognizant Helping to Modernize Infrastructure and..
25/1/202412:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202412:11EDGAR2Form SC 13D/A - General statement of acquisition of..
19/1/202412:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..

Dernières Valeurs Consultées

Delayed Upgrade Clock